Lv77
4680 积分 2022-05-23 加入
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
15天前
已完结
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
21天前
已完结
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
29天前
已完结
Esophageal Cancer: Overview, Risk Factors, and Reasons for the Rise
1个月前
已完结
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer
1个月前
已完结
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010–02)
1个月前
已完结
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
1个月前
已完结
Exploiting the folate receptor α in oncology
2个月前
已完结
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
3个月前
已完结
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
3个月前
已完结
皖公网安备34019202002308
